Immunohistochemical staining of fixed tumour tissues revealed non-significantly reduced levels of proliferative marker, MCM2, in ASO-361-3p-treated tumours vscontrols, but no change in cleaved PARP protein levels (Fig. 4E, Supplementary Fig. 14). Here, MCM2 is linked to neoplasm.